Cardinal Health Specialty Solutions, KEW Group Bring Power of Personalized Medicine to Community Oncologists
Cardinal Health Specialty Solutions and KEW Group, Inc., a privately held oncology services company, have announced an agreement for the two companies to make KEW's state-of-the-art diagnostic services available to Specialty Solutions' community oncology customers.
KEW is a privately held oncology services company that is focused on revolutionising cancer care by empowering all oncologists to access and apply genomic insights to design optimal, individualised treatment approaches for as many patients as possible.
"We are committed to working with all players in the healthcare system to ensure the right patients are treated at the right time, with the most effective medication, in the most convenient, accessible setting," said Scott Howell, M.D., senior vice president of Clinical Services for Cardinal Health Specialty Solutions. "Our expanded agreement with KEW helps us deliver on that commitment, by providing community oncologists with access to advanced diagnostics tools that can help them make the best, most informed treatment decisions for their patients, while improving the overall cost effectiveness of care."
Cardinal Health Specialty Solutions customers will now have access to KEW's CancerPlex, a highly versatile and comprehensive genetic test providing accurate, thorough and timely molecular diagnosis of patients' solid tumors, providing oncologists the ability to manage their treatment decisions with the precision provided by personalised medicine. CancerPlex:
• Simultaneously provides complete sequence coverage of more than 410 cancer genes;
• Simplifies and streamlines the test-ordering process by eliminating serial "hotspot" tests;
• Delivers a comprehensive report, including actionable data;
• Informs physicians of optimal treatment options using approved therapies and available clinical trials; and
• Supports clinical trial enrollment by providing oncologists with required molecular data.
CancerPlex testing is performed at KEW's state-of-the-art CLIA laboratory. After an oncologist orders CancerPlex, KEW facilitates tumour specimen retrieval from the patient's pathologist; analyses the specimen at its CLIA lab and then reports the findings to the oncologist. This process reveals genetic and genomic changes that impact a patient's optimal treatment options, and which may otherwise remain undiscovered by limited genetic screening or less comprehensive tests. KEW then provides the oncologist with information on diagnostic findings and potential treatment options (including clinical trials) that are most appropriate for the patient.
"We are excited to make our leading-edge molecular sequencing tumor diagnostics tools available to the nationwide network of community oncologists served by Cardinal Health Specialty Solutions," said Scott Schell, CEO of KEW Group. "We look forward to working with Specialty Solutions and community oncologists — who treat 80% of cancer patients in the US — empowering them with the ability to provide personalised medicine treatments previously only available at large cancer treatment and academic centers."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance